1
|
Malley R, Lu YJ, Sebastian S, Zhang F, Willer DO. Multiple antigen presenting system (MAPS): state of the art and potential applications. Expert Rev Vaccines 2024; 23:196-204. [PMID: 38174559 DOI: 10.1080/14760584.2023.2299384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Accepted: 12/21/2023] [Indexed: 01/05/2024]
Abstract
INTRODUCTION Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components. AREAS COVERED This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings. EXPERT OPINION The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.
Collapse
Affiliation(s)
- Richard Malley
- Division of Infectious Diseases, Department of Medicine, Boston Children's Hospital, Boston, MA, USA
| | - Ying-Jie Lu
- Division of Infectious Diseases, Department of Medicine, Boston Children's Hospital, Boston, MA, USA
| | | | - Fan Zhang
- Division of Infectious Diseases, Department of Medicine, Boston Children's Hospital, Boston, MA, USA
| | - David O Willer
- GSK, Global Medical Affairs, Vaccines Research and Development, Mississauga, Ontario, Canada
| |
Collapse
|
2
|
Huq AFMA, Biswas SK, Sheam MM, Syed SB, Elahi MT, Tang SS, Rahman MM, Roy AK, Paul DK. Identification and antibiotic pattern analysis of bacillary dysentery causing bacteria isolated from stool samples of infected patients. Biologia (Bratisl) 2023; 78:873-885. [PMID: 36573069 PMCID: PMC9769483 DOI: 10.1007/s11756-022-01299-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 12/13/2022] [Indexed: 12/24/2022]
Abstract
Bacillary dysentery is a type of dysentery and a severe form of shigellosis. This dysentery is usually restricted to Shigella infection, but Salmonella enterica and enteroinvasive Escherichia coli strains are also known as this infection's causative agents. The emergence of drug-resistant, bacillary dysentery-causing pathogens is a global burden, especially for developing countries with poor hygienic environments. This study aimed to isolate, identify, and determine the drug-resistant pattern of bacillary dysentery-causing pathogens from the stool samples of the Kushtia region in Bangladesh. Hence, biochemical tests, serotyping, molecular identification, and antibiotic profiling were performed to characterize the pathogens. Among one hundred fifty (150) stool samples, 18 enteric bacterial pathogens were isolated and identified, where 12 were Shigella strains, 5 were S. enterica sub spp. enterica strains and one was the E.coli strain. Among 12 Shigella isolates, 8 were Shigella flexneri 2a serotypes, and 4 were Shigella sonnei Phage-II serotypes. Except for three Salmonella strains, all isolated strains were drug-resistant (83%), whereas 50% were multidrug-resistant (MDR), an alarming issue for public health. In antibiotic-wise analysis, the isolated pathogens showed the highest resistance against nalidixic acid (77.78%), followed by tetracycline (38.89%), kanamycin (38.89%), amoxicillin (27.78%), streptomycin (27.78%), cefepime (22.22%), ceftriaxone (22.22%), ampicillin (16.67%), ciprofloxacin (16.67%), and chloramphenicol (16.67%). The existence of MDR organisms that cause bacillary dysentery in the Kushtia area would warn the public to be more health conscious, and physicians would administer medications cautiously. The gradual growth of MDR pathogenic microorganisms needs immediate attention, and the discovery of effective medications must take precedence. Supplementary information The online version contains supplementary material available at 10.1007/s11756-022-01299-x.
Collapse
Affiliation(s)
- Abul Fazel Mohammad Aminul Huq
- Department of Applied Nutrition and Food Technology, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| | - Sudhangshu Kumar Biswas
- Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| | - Mohammad Moinuddin Sheam
- Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| | - Shifath Bin Syed
- Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
- Department of Animal Sciences, College of Agricultural, Human and Natural Resource Sciences, Washington State University, Pullman, WA USA
| | - Mohammad Toufiq Elahi
- Department of Applied Nutrition and Food Technology, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| | - Swee-Seong Tang
- Division of Microbiology, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
| | - Mohammad Mizanur Rahman
- Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| | - Apurba Kumar Roy
- Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Rajshahi, 6205 Rajshahi, Bangladesh
| | - Dipak Kumar Paul
- Department of Applied Nutrition and Food Technology, Faculty of Biological Sciences, Islamic University, 7003 Kushtia, Bangladesh
| |
Collapse
|
3
|
Afonnikova S, Komissarov A, Kuchur P. Unique or not unique? Comparative genetic analysis of bacterial O-antigens from the Oxalobacteraceae family. Vavilovskii Zhurnal Genet Selektsii 2022; 26:810-818. [PMID: 36694719 PMCID: PMC9834719 DOI: 10.18699/vjgb-22-98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 10/10/2022] [Accepted: 10/26/2022] [Indexed: 01/06/2023] Open
Abstract
Many plants and animals have symbiotic relationships with microorganisms, including bacteria. The interactions between bacteria and their hosts result in different outcomes for the host organism. The outcome can be neutral, harmful or have beneficial effects for participants. Remarkably, these relationships are not static, as they change throughout an organism's lifetime and on an evolutionary scale. One of the structures responsible for relationships in bacteria is O-antigen. Depending on the characteristics of its components, the bacteria can avoid the host's immune response or establish a mutualistic relationship with it. O-antigen is a key component in Gram-negative bacteria's outer membrane. This component facilitates interaction between the bacteria and host immune system or phages. The variability of the physical structure is caused by the genomic variability of genes encoding O-antigen synthesis components. The genes and pathways of O-polysaccharide (OPS) synthesis were intensively investigated mostly for Enterobacteriaceae species. Considering high genetic and molecular diversity of this structure even between strains, these findings may not have caught the entire variety possibly presented in non-model species. The current study presents a comparative analysis of genes associated with O-antigen synthesis in bacteria of the Oxalobacteraceae family. In contrast to existing studies based on PCR methods, we use a bioinformatics approach and compare O- antigens at the level of clusters rather than individual genes. We found that the O-antigen genes of these bacteria are represented by several clusters located at a distance from each other. The greatest similarity of the clusters is observed within individual bacterial genera, which is explained by the high variability of O-antigens. The study describes similarities of OPS genes inherent to the family as a whole and also considers individual unique cases of O-antigen genetic variability inherent to individual bacteria.
Collapse
Affiliation(s)
- S.D. Afonnikova
- Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RussiaNovosibirsk State University, Novosibirsk, Russia
| | | | - P.D. Kuchur
- ITMO University, SCAMT Institute, St. Petersburg, Russia
| |
Collapse
|
4
|
Naini A, Bartetzko MP, Sanapala SR, Broecker F, Wirtz V, Lisboa MP, Parameswarappa SG, Knopp D, Przygodda J, Hakelberg M, Pan R, Patel A, Chorro L, Illenberger A, Ponce C, Kodali S, Lypowy J, Anderson AS, Donald RGK, von Bonin A, Pereira CL. Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice. JACS AU 2022; 2:2135-2151. [PMID: 36186572 PMCID: PMC9516715 DOI: 10.1021/jacsau.2c00401] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 08/19/2022] [Accepted: 08/22/2022] [Indexed: 06/01/2023]
Abstract
Extraintestinal pathogenic Escherichia coli (ExPEC) is a major health concern due to emerging antibiotic resistance. Along with O1A, O2, and O6A, E. coli O25B is a major serotype within the ExPEC group, which expresses a unique O-antigen. Clinical studies with a glycoconjugate vaccine of the above-mentioned O-types revealed O25B as the least immunogenic component, inducing relatively weak IgG titers. To evaluate the immunological properties of semisynthetic glycoconjugate vaccine candidates against E. coli O25B, we here report the chemical synthesis of an initial set of five O25B glycan antigens differing in length, from one to three repeat units, and frameshifts of the repeat unit. The oligosaccharide antigens were conjugated to the carrier protein CRM197. The resulting semisynthetic glycoconjugates induced functional IgG antibodies in mice with opsonophagocytic activity against E. coli O25B. Three of the oligosaccharide-CRM197 conjugates elicited functional IgGs in the same order of magnitude as a conventional CRM197 glycoconjugate prepared with native O25B O-antigen and therefore represent promising vaccine candidates for further investigation. Binding studies with two monoclonal antibodies (mAbs) revealed nanomolar anti-O25B IgG responses with nanomolar K D values and with varying binding epitopes. The immunogenicity and mAb binding data now allow for the rational design of additional synthetic antigens for future preclinical studies, with expected further improvements in the functional antibody responses. Moreover, acetylation of a rhamnose residue was shown to be likely dispensable for immunogenicity, as a deacylated antigen was able to elicit strong functional IgG responses. Our findings strongly support the feasibility of a semisynthetic glycoconjugate vaccine against E. coli O25B.
Collapse
Affiliation(s)
- Arun Naini
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Max Peter Bartetzko
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Someswara Rao Sanapala
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Felix Broecker
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Victoria Wirtz
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Marilda P. Lisboa
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | | | - Daniel Knopp
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Jessica Przygodda
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Matthias Hakelberg
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Rosalind Pan
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Axay Patel
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Laurent Chorro
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Arthur Illenberger
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Christopher Ponce
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Srinivas Kodali
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Jacqueline Lypowy
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | | | - Robert G. K. Donald
- Pfizer
Vaccine Research and Development, Pearl River, New York 10965, United States
| | - Arne von Bonin
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| | - Claney L. Pereira
- Vaxxilon
Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany
| |
Collapse
|
5
|
Cross reacting material (CRM197) as a carrier protein for carbohydrate conjugate vaccines targeted at bacterial and fungal pathogens. Int J Biol Macromol 2022; 218:775-798. [PMID: 35872318 DOI: 10.1016/j.ijbiomac.2022.07.137] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/14/2022] [Accepted: 07/18/2022] [Indexed: 11/22/2022]
Abstract
This paper gives an overview of conjugate glycovaccines which contain recombinant diphtheria toxoid CRM197 as a carrier protein. A special focus is given to synthetic methods used for preparation of neoglycoconjugates of CRM197 with oligosaccharide epitopes of cell surface carbohydrates of pathogenic bacteria and fungi. Syntheses of commercial vaccines and laboratory specimen on the basis of CRM197 are outlined briefly.
Collapse
|
6
|
Biophysical Reviews’ “meet the editors series”—a profile of Steve Harding’s career in macromolecular hydrodynamics. Biophys Rev 2022; 14:605-610. [DOI: 10.1007/s12551-022-00963-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Accepted: 05/24/2022] [Indexed: 01/14/2023] Open
|
7
|
Hall D. Biophysical reviews: call for nominations for the 2023 Michèle Auger Award. Biophys Rev 2022; 14:599-603. [PMID: 38625311 PMCID: PMC9210329 DOI: 10.1007/s12551-022-00973-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/08/2022] [Indexed: 12/01/2022] Open
Abstract
This Editorial for Issue 3 (Vol. 14 2022) of Biophysical Reviews first describes the Issue's contents (five commentaries/editorials within the front matter and seven review/letter articles appearing within the main body) before going on to discuss a number of matters of potential importance to the journal and its readers. Amongst this second tranche of content is the opening of the call for nominations for the 2023 Michèle Auger Award for Young Scientists' Independent Research.
Collapse
Affiliation(s)
- Damien Hall
- WPI Nano Life Science Institute, Kanazawa University, Ishikawa 920-1164 Kakumamachi, Kanazawa, Japan
- Department of Applied Physics, Aalto University, FI-00076 Aalto, Finland
| |
Collapse
|
8
|
van
der Put RMF, Smitsman C, de Haan A, Hamzink M, Timmermans H, Uittenbogaard J, Westdijk J, Stork M, Ophorst O, Thouron F, Guerreiro C, Sansonetti PJ, Phalipon A, Mulard LA. The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella. ACS CENTRAL SCIENCE 2022; 8:449-460. [PMID: 35559427 PMCID: PMC9088300 DOI: 10.1021/acscentsci.1c01479] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Indexed: 05/12/2023]
Abstract
Shigella, the causative agent of shigellosis, is among the main causes of diarrheal diseases with still a high morbidity in low-income countries. Relying on chemical synthesis, we implemented a multidisciplinary strategy to design SF2a-TT15, an original glycoconjugate vaccine candidate targeting Shigella flexneri 2a (SF2a). Whereas the SF2a O-antigen features nonstoichiometric O-acetylation, SF2a-TT15 is made of a synthetic 15mer oligosaccharide, corresponding to three non-O-acetylated repeats, linked at its reducing end to tetanus toxoid by means of a thiol-maleimide spacer. We report on the scale-up feasibility under GMP conditions of a high yielding bioconjugation process established to ensure a reproducible and controllable glycan/protein ratio. Preclinical and clinical batches complying with specifications from ICH guidelines, WHO recommendations for polysaccharide conjugate vaccines, and (non)compendial tests were produced. The obtained SF2a-TT15 vaccine candidate passed all toxicity-related criteria, was immunogenic in rabbits, and elicited bactericidal antibodies in mice. Remarkably, the induced IgG antibodies recognized a large panel of SF2a circulating strains. These preclinical data have paved the way forward to the first-in-human study for SF2a-TT15, demonstrating safety and immunogenicity. This contribution discloses the yet unreported feasibility of the GMP synthesis of conjugate vaccines featuring a unique homogeneous synthetic glycan hapten fine-tuned to protect against an infectious disease.
Collapse
Affiliation(s)
| | | | - Alex de Haan
- Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Martin Hamzink
- Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | | | | | - Janny Westdijk
- Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Michiel Stork
- Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Olga Ophorst
- Intravacc, P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Françoise Thouron
- Institut
Pasteur, U1202 Inserm, Unité
de Pathogénie Microbienne Moléculaire, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Catherine Guerreiro
- Institut
Pasteur, Université Paris Cité, CNRS UMR3523, Unité de Chimie des Biomolécules, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Philippe J. Sansonetti
- Institut
Pasteur, U1202 Inserm, Unité
de Pathogénie Microbienne Moléculaire, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
- Chaire
de Microbiologie et Maladies Infectieuses, Collège de France, 11, place Marcelin Berthelot, 75005 Paris, France
| | - Armelle Phalipon
- Institut
Pasteur, U1202 Inserm, Unité
de Pathogénie Microbienne Moléculaire, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Laurence A. Mulard
- Institut
Pasteur, Université Paris Cité, CNRS UMR3523, Unité de Chimie des Biomolécules, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
| |
Collapse
|
9
|
Pakbin B, Basti AA, Khanjari A, Brück WM, Azimi L, Karimi A. Development of high-resolution melting (HRM) assay to differentiate the species of Shigella isolates from stool and food samples. Sci Rep 2022; 12:473. [PMID: 35013489 PMCID: PMC8748861 DOI: 10.1038/s41598-021-04484-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 12/23/2021] [Indexed: 11/09/2022] Open
Abstract
Shigella species, a group of intracellular foodborne pathogens, are the main causes of bacillary dysentery and shigellosis in humans worldwide. It is essential to determine the species of Shigella in outbreaks and food safety surveillance systems. The available immunological and molecular methods for identifying Shigella species are relatively complicated, expensive and time-consuming. High resolution melting (HRM) assay is a rapid, cost-effective, and easy to perform PCR-based method that has recently been used for the differentiation of bacterial species. In this study, we designed and developed a PCR-HRM assay targeting rrsA gene to distinguish four species of 49 Shigella isolates from clinical and food samples and evaluated the sensitivity and specificity of the assay. The assay demonstrated a good analytical sensitivity with 0.01–0.1 ng of input DNA template and an analytical specificity of 100% to differentiate the Shigella species. The PCR-HRM assay also was able to identify the species of all 49 Shigella isolates from clinical and food samples correctly. Consequently, this rapid and user-friendly method demonstrated good sensitivity and specificity to differentiate species of the Shigella isolates from naturally contaminated samples and has the potential to be implemented in public health and food safety surveillance systems.
Collapse
Affiliation(s)
- Babak Pakbin
- Institute for Life Technologies, University of Applied Sciences Western Switzerland Valais-Wallis, 1950 Sion 2, Sierre, Switzerland.,Department of Food Hygiene and Quality of Control, Faculty of Veterinary Medicine, University of Tehran, P.O. Box: 14155-6453, Tehran, Iran
| | - Afshin Akhondzadeh Basti
- Department of Food Hygiene and Quality of Control, Faculty of Veterinary Medicine, University of Tehran, P.O. Box: 14155-6453, Tehran, Iran.
| | - Ali Khanjari
- Department of Food Hygiene and Quality of Control, Faculty of Veterinary Medicine, University of Tehran, P.O. Box: 14155-6453, Tehran, Iran
| | - Wolfram Manuel Brück
- Institute for Life Technologies, University of Applied Sciences Western Switzerland Valais-Wallis, 1950 Sion 2, Sierre, Switzerland
| | - Leila Azimi
- Pediatric Infections Research Center, Research Institute of Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Abdollah Karimi
- Pediatric Infections Research Center, Research Institute of Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
10
|
Abstract
The current issue (volume 13 issue 6, 2021) is a Special Issue jointly dedicated to scientific content presented at the 20th triennial IUPAB Congress that was held in conjunction with both the 45th Annual Meeting of the Brazilian Biophysical Society (Sociedade Brasileira de Biofísica - SBBf) and the 50th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology (Sociedade Brasileira de Bioquímica e Biologia Molecular - SBBq). In addition to describing the scientific and nonscientific content arising from the meeting this sub-editorial also provides a look back at some of the high points for Biophysical Reviews in the year 2021 before going on to describe a number of matters of interest to readers of the journal in relation to the coming year of 2022.
Collapse
Affiliation(s)
- Damien Hall
- WPI Nano Life Science Institute, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa 920-1164 Japan
- Department of Applied Physics, Aalto University, FI-00076 Aalto, Finland
| |
Collapse
|
11
|
Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines. Microorganisms 2021; 9:microorganisms9081707. [PMID: 34442786 PMCID: PMC8400138 DOI: 10.3390/microorganisms9081707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 08/02/2021] [Accepted: 08/07/2021] [Indexed: 12/04/2022] Open
Abstract
Typhoid conjugate vaccines (TCV) are effective in preventing enteric fever caused by Salmonella enterica serovar Typhi in Southeast Asia and Africa. To facilitate vaccination with the Vi capsular polysaccharide–tetanus toxoid conjugate vaccine, Typbar TCV, and allow it to be transported and stored outside a cold chain just prior to administration, an extended controlled-temperature conditions (ECTC) study was performed to confirm the quality of the vaccine at 40 °C for 3 days at the end of its shelf-life (36 months at 2–8 °C). Studies performed in parallel by the vaccine manufacturer, Bharat Biotech International Limited, and an independent national control laboratory (NIBSC) monitored its stability-indicating parameters: O-acetylation of the Vi polysaccharide, integrity of the polysaccharide–protein conjugate, and its molecular size and pH. ECTC samples stored at 40 °C and 45 °C in comparison with control samples stored at 4 °C and 55 or 56 °C, were shown to have stable O-acetylation and pH; only very slight increases in the percentage of free saccharide and corresponding decreases in molecular size were observed. The deoxycholate method for precipitating conjugated polysaccharide was very sensitive to small incremental increases in percentage of free saccharide, in line with storage temperature and duration. This extended ECTC study demonstrated minimal structural changes to the Vi polysaccharide and conjugate vaccine and a stable formulation following extended exposure to elevated temperatures for the desired durations. This outcome supports the manufacturer’s ECTC claim for the vaccine to be allowed to be taken outside the cold chain before its administration.
Collapse
|
12
|
Abstract
Run by the International Union for Pure and Applied Biophysics (IUPAB) and published by Springer Nature, Biophysical Reviews is an international journal dedicated to publishing topical review articles in the areas of (i) biology-related physics, (ii) structural biology, and (iii) molecular biology. This Editorial for Volume 13, Issue 2 of Biophysical Reviews provides a brief summary of the contents of the current Issue and then describes some matters important to the journal for 2021.
Collapse
Affiliation(s)
- Damien Hall
- WPI Nano Life Science Institute, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa 920-1164 Japan
- Department of Applied Physics, Alto University, FI-00076 Aalto, Finland
| |
Collapse
|